UniQure gets $450M upfront to license hemophilia B gene therapy
May 06, 2021 at 14:25 PM EDT
The Netherlands-based biotech with U.S. headquarters in Lexington has licensed its investigational gene therapy for hemophilia B to Pennsylvania's CSL Behring for an upfront payment of $450 million, with an additional $1.6 billion in milestone payments, plus royalties.
